Expression of concern: "Could the multicomponent meningococcal serogroup B vaccine (4CMenB) control Neisseria meningitidis capsular group X outbreaks in Africa?" and "Bactericidal antibody against a representative epidemiological meningococcal serogroup"
- PMID: 32624253
- DOI: 10.1016/j.vaccine.2020.06.048
Expression of concern: "Could the multicomponent meningococcal serogroup B vaccine (4CMenB) control Neisseria meningitidis capsular group X outbreaks in Africa?" and "Bactericidal antibody against a representative epidemiological meningococcal serogroup"
Conflict of interest statement
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Expression of concern for
-
Could the multicomponent meningococcal serogroup B vaccine (4CMenB) control Neisseria meningitidis capsular group X outbreaks in Africa?Vaccine. 2013 Feb 4;31(7):1113-6. doi: 10.1016/j.vaccine.2012.12.022. Epub 2012 Dec 20. Vaccine. 2013. PMID: 23261039
-
Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage.Vaccine. 2013 Oct 9;31(43):4968-74. doi: 10.1016/j.vaccine.2013.08.006. Epub 2013 Aug 14. Vaccine. 2013. PMID: 23954380
Publication types
LinkOut - more resources
Full Text Sources
